VistaGen Therapeutics

VTGN · Nasdaq · United States

Share price · VTGN

$0.20-0.04 (-17.56%) 3M

close as of 2026-11-18 · 24h delayed · vol 2.1M (2.7x 30-day avg)

Loading chart…

Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento

Compare with peers →

Unusual price moves

Days when VTGN's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked

  1. 23 Sep 2026+46.5%
  2. 30 Jun 2026-70.3%
  3. 26 Jun 2026+13.9%
  4. 16 Jun 2026+20.4%
  5. 11 May 2026+10.3%
  6. 17 Dec 2025-80.3%

    Nothing announced by VTGN that day or the session before.

  7. 11 Dec 2025-12.8%
  8. 4 Dec 2025+14.7%
  9. 2 Dec 2025-18.7%

    Nothing announced by VTGN that day or the session before.

Share of unusual movement by asset

For each asset, the share of VTGN's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.

AssetEvent daysShare of unusual movement
fasedienol
events and moves
935%
AV-101
events and moves
1shown from 8 days
Assets with fewer than 8 event days, together—0%
Other company news (earnings, financing, releases naming no asset)—9%
Sessions with no dated event—56%

Assets

(3 total)
3Total Assets
0Approved
1Phase 3 / Filed
2Phase 1–2 / Early
3Diseases
Quick filter:
Showing 3 of 3 assets
Target & Modality
Phase 3
Nasal chemosensory receptorsSmall molecule
Social Anxiety Disorder
AV-101No recent activity
Phase 2
NMDA receptorSmall molecule
Major Depressive DisorderParkinson's Disease
Preclinical / Unstaged
—Small molecule
Major Depressive Disorder

Upcoming events

No upcoming trial completions or earnings dates on record for this company's assets.

Regulatory and conference events

(3)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

6 August 2026Topline resultfasedienolExploratory Phase 2 repeat-dose study of fasedienol: primary endpoint not statistically significant
VistaGen Therapeutics · Source ↗
30 June 2026Topline resultfasedienolPhase 3 PALISADE-4 of fasedienol did not meet its primary endpoint
VistaGen Therapeutics · Source ↗
June 2026Topline resultfasedienolPALISADE-4 randomized portion missed primary endpoint

Financial reports

Quarterly & interim (18)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q3$0.1M$6.5M$11M+ $9.1M short-term inv.$11M-$12M operating cash flowreport ↗
View 17 more
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q2$1.5M$11M$17M+ $15M short-term inv.$13M-$15M operating cash flowreport ↗
2025-Q4$0.3M$14M$47M+ $14M short-term inv.$19M-$18M operating cash flowreport ↗
2025-Q3$0.3M$16M$63M+ $14M short-term inv.$19M-$14M operating cash flowreport ↗
2025-Q2$0.2M$12M$49M+ $14M short-term inv.$15M-$19M operating cash flowreport ↗
2024-Q4$0.2M$11M$75M+ $14M short-term inv.$14M-$10M operating cash flowreport ↗
2024-Q3$0.2M$10M$84M+ $13M short-term inv.$13M-$11M operating cash flowreport ↗
2024-Q2$0.1M$7.7M$103M+ $5.5M short-term inv.$11M-$11M operating cash flowreport ↗
2023-Q4$0.4M$4.5M$127M$6.3M-$4.5M operating cash flowreport ↗
2023-Q3$0.3M$3.9M$38M$6.6M-$6.2M operating cash flowreport ↗
2023-Q2$0.2M$4.2M$9.6M$6.9M-$7.9M operating cash flowreport ↗
2023-Q1—$9.3M$17M$12M-$7.5M operating cash flowreport ↗
2022-Q4—$6.8M$25M$9.8M-$9.9M operating cash flowreport ↗
2022-Q3—$13M$35M$17M-$16M operating cash flowreport ↗
2022-Q2$0.3M$15M$52M$20M-$16M operating cash flowreport ↗
2022-Q1—$12M$68M$17M-$16M operating cash flowreport ↗
2021-Q4$0.4M$8.0M$84M$11M-$12M operating cash flowreport ↗
2021-Q3$0.4M$10M$94M$13M-$11M operating cash flowreport ↗

Annual history (6 years)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-FY$1.3M$55M$31M+ $15M short-term inv.$17M-$66M operating cash flowreport ↗

VistaGen reported fiscal 2026 revenue of $1.27M, up 159.2% YoY, and R&D spend of $54.97M, up 39.6% YoY. Cash and equivalents were $30.79M, or $45.4M including marketable securities, and the company reported a net loss of $69.68M with a quarterly net burn of $69.69M.

The company completed the randomized portion of the PALISADE-4 Phase 3 trial of fasedienol for acute social anxiety disorder, with topline results expected in June 2026, and also completed the randomized portion of a fasedienol Phase 2 repeat-dose study, with topline results expected in the third quarter of 2026. Preliminary positive data were reported from the open-label extension of PALISADE-3, and the company said it had met minimum ICH E1 safety exposure recommendations across the fasedienol program. Refisolone received an FDA Study May Proceed letter under its IND for menopausal vasomotor symptoms, while itruvone preparation continued for major depressive disorder. Management also highlighted recent executive appointments and targeted cost-management initiatives, and stated that existing cash should fund operations into 2027.

View 5 more years
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-FY$0.5M$39M$67M+ $13M short-term inv.$13M-$42M operating cash flowreport ↗
2024-FY$1.1M$20M$119M+ $0 short-term inv.$7.3M-$26M operating cash flowreport ↗
2023-FY—$44M$17M$15M-$50M operating cash flowreport ↗
2022-FY$1.1M$35M$68M$12M-$45M operating cash flowreport ↗
2021-FY$1.1M$12M$103M$4.5M-$12M operating cash flowreport ↗

Insider transactions

Open-market activity, trailing 12 months: 0 purchases (—), 0 sales (—). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.

Source
2026-07-29Williamson Douglas J · directorAward / grant (derivative)40,826——Form 4
2026-06-30Singh Shawn · director, President and CEOAward / grant36,818$0.19$7KForm 4
2026-06-30Tressler Nick B. · Chief Financial OfficerAward / grant11,712$0.19$2KForm 4
2026-06-30Adler Reid G. · Chief Legal OfficerAward / grant36,818$0.19$7KForm 4
2026-05-18Angelov Angel S · Chief Medical OfficerAward / grant (derivative)150,000——Form 4
2026-04-07Adler Reid G. · Chief Legal OfficerAward / grant (derivative)18,753——Form 4
2026-04-07Cote Elissa S. · Chief Corp Development OfficerAward / grant (derivative)75,000——Form 4
2026-04-07Prince Joshua S. · Chief Operating OfficerAward / grant (derivative)18,752——Form 4

Institutional holders

From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 56 reporting institutions held 15.3M shares ($7.8M, 34.6% of shares outstanding).

#InstitutionSharesValue
1ORBIMED ADVISORS LLC3,060,000$1.7M
2TCG Crossover Management, LLC2,676,580$1.5M
3VANGUARD CAPITAL MANAGEMENT LLC1,574,200$900K
4ADAR1 Capital Management, LLC751,141$429K
5Ikarian Capital, LLC519,077$297K
6TWO SIGMA INVESTMENTS, LP469,619$268K
7GEODE CAPITAL MANAGEMENT, LLC453,391$259K
8BlackRock, Inc.448,507$256K
9MILLENNIUM MANAGEMENT LLC430,404$246K
10LUMINUS MANAGEMENT LLC396,053$226K
11RENAISSANCE TECHNOLOGIES LLC291,300$166K
12AdvisorShares Investments LLC277,110$158K
13JANE STREET GROUP, LLC272,811$156K
14VANGUARD FIDUCIARY TRUST CO217,700$125K
15STEMPOINT CAPITAL LP1,233,498$116K